TC-E 5002

Selective KDM2/7 inhibitor CAS# 1453071-47-0

TC-E 5002

Catalog No. BCC5608----Order now to get a substantial discount!

Product Name & Size Price Stock
TC-E 5002: 5mg $127 In Stock
TC-E 5002: 10mg Please Inquire In Stock
TC-E 5002: 20mg Please Inquire Please Inquire
TC-E 5002: 50mg Please Inquire Please Inquire
TC-E 5002: 100mg Please Inquire Please Inquire
TC-E 5002: 200mg Please Inquire Please Inquire
TC-E 5002: 500mg Please Inquire Please Inquire
TC-E 5002: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of TC-E 5002

Number of papers citing our products

Chemical structure

TC-E 5002

3D structure

Chemical Properties of TC-E 5002

Cas No. 1453071-47-0 SDF Download SDF
PubChem ID 71735843 Appearance Powder
Formula C15H27NO4 M.Wt 285.38
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in 1eq. NaOH and to 100 mM in DMSO
Chemical Name 3-[9-cyclopropylnonanoyl(hydroxy)amino]propanoic acid
SMILES C1CC1CCCCCCCCC(=O)N(CCC(=O)O)O
Standard InChIKey NEHSERYKENINRH-UHFFFAOYSA-N
Standard InChI InChI=1S/C15H27NO4/c17-14(16(20)12-11-15(18)19)8-6-4-2-1-3-5-7-13-9-10-13/h13,20H,1-12H2,(H,18,19)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of TC-E 5002

DescriptionSelective histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). Inhibits growth of HeLa and KYSE-150 cancer cells in vitro.

TC-E 5002 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

TC-E 5002 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of TC-E 5002

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.5041 mL 17.5205 mL 35.041 mL 70.082 mL 87.6025 mL
5 mM 0.7008 mL 3.5041 mL 7.0082 mL 14.0164 mL 17.5205 mL
10 mM 0.3504 mL 1.752 mL 3.5041 mL 7.0082 mL 8.7602 mL
50 mM 0.0701 mL 0.3504 mL 0.7008 mL 1.4016 mL 1.752 mL
100 mM 0.035 mL 0.1752 mL 0.3504 mL 0.7008 mL 0.876 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on TC-E 5002

Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.[Pubmed:30183076]

Int J Cancer. 2018 Dec 1;143(11):2849-2861.

Prostate cancer can be controlled by androgen-hormone treatment until the cancer becomes refractory. It is believed that hormone sensitivity is largely dependent on androgen receptor (AR) activity. Here, we found the histone demethylase KDM7A which demethylates histone H3K27 to be overexpressed in enzalutamide resistant castration-resistant prostate cancer cell line C4-2b, and investigated the molecular mechanism whereby androgen receptor activity is regulated by KDM7A. We engineered AR-positive LNCaP cells to stably express a short-hairpin RNA against KDM7A mRNA from a lentiviral vector. By measuring AR downstream gene expression after androgen stimulation, we found that a KDM7A-deficient cell line showed lower AR downstream gene expression compared to a control cell. KDM7A knock-down in LNCaP cell line caused decreased cell proliferation. Western blot analysis with modified-histone antibody revealed that the KDM7A-knock-down LNCaP cell line had increased H3K27 di-methylation. We confirmed KDM7A binding on AR target-gene promoters after hormone stimulation in chromatin-immunoprecipitation experiments. And increased H3K27 di-methylation was observed in KDM7A knock-down LNCaP stable cell. Treatment with KDM7A inhibitor, TC-E 5002, reduced proliferation and induced apoptosis of prostate cancer cells. Finally, we observed that the KDM7A protein was significantly upregulated in prostate cancer tissue, and that this difference correlated with the Gleason score. These data suggested that KDM7A is potentially a good therapeutic target for prostate cancer drugs and can be used as potentially a good prognostic indicator for prostate cancer and related treatment strategies.

Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.[Pubmed:23964788]

J Med Chem. 2013 Sep 26;56(18):7222-31.

Histone N(epsilon)-methyl lysine demethylases KDM2/7 have been identified as potential targets for cancer therapies. On the basis of the crystal structure of KDM7B, we designed and prepared a series of hydroxamate analogues bearing an alkyl chain. Enzyme assays revealed that compound 9 potently inhibits KDM2A, KDM7A, and KDM7B, with IC50s of 6.8, 0.2, and 1.2 muM, respectively. While inhibitors of KDM4s did not show any effect on cancer cells tested, the KDM2/7-subfamily inhibitor 9 exerted antiproliferative activity, indicating the potential for KDM2/7 inhibitors as anticancer agents.

Keywords:

TC-E 5002,1453071-47-0,Natural Products,Histone Demethylases, buy TC-E 5002 , TC-E 5002 supplier , purchase TC-E 5002 , TC-E 5002 cost , TC-E 5002 manufacturer , order TC-E 5002 , high purity TC-E 5002

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: